Atlas Trials

A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT07658352 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07658352
Sponsor
Shanghai Helioson Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
B-Cell Non-Hodgkin Lymphoma
Start date
2026-06-26
Primary completion
2029-06-26
Enrollment
114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.